G
Genomenon
Biotech & Life Sciences · Ann Arbor, United States · Founded 2014
Genomenon develops software tools to rapidly and autonomously prioritize data points for decision-making MoreLess
Genomenon is a genomic health IT company that provides tools and services for genetic testing labs and pharmaceutical companies. The company's flagship product, the Mastermind Genomic Search Engine, is a comprehensive database of genomic evidence from scientific literature. This tool allows users to search for information on genetic variants, view the supporting evidence, and understand the clinical significance of those variants. The platform is designed to accelerate the process of interpreting genomic data, which is a critical step in diagnosing and treating genetic diseases.
Genomenon's business model is based on providing access to its Mastermind platform through a subscription-based service. They offer different tiers of access depending on the needs of the client, which range from individual researchers to large-scale clinical laboratories and pharmaceutical companies. In addition to its software platform, the company also offers expert curation services, where their team of scientists and curators will manually review and interpret genomic data for clients. This combination of a software-as-a-service (SaaS) platform and specialized consulting services allows Genomenon to cater to a wide range of customers within the genomics market.
Keywords: genomic intelligence, genomic data, genetic testing, pharmaceutical, Mastermind, genomic search engine, genetic variants, clinical diagnostics, SaaS, consulting services
Company overview
Genomenon company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- Ann Arbor, United States
- Employees
- 136
- Open positions
- 7
- Dealroom signal
- 65.3
- Investment activity
- 1 companies · latest Jun 2023
- Capital deployed
- —
- Preferred round
- ACQUISITION
Valuation & funding
Genomenon funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Jun 2024 | $6M | $100M | Undisclosed | ↗ |
| SERIES B✓Equity / VC | Mar 2022 | $20M | $80M | Michigan Angel Fund · Spring Mountain Capital · IrishAngels · Green Park & Golf Ventures | ↗ |
| GRANT✓Other financing | Feb 2022 | $1.7M | — | National Institutes of Health | ↗ |
| SERIES AEquity / VC | Mar 2021 | $5.3M | $21M | Undisclosed | — |
| EARLY VC✓Equity / VC | Jan 2019 | $2.5M | $10M | IrishAngels | — |
| GRANT✓Other financing | Apr 2017 | National Institutes of Health | — | ||
| SEED✓Equity / VC | Nov 2016 | Undisclosed | — | ||
| SEED✓Equity / VC | Jan 2016 | InvestMichigan · Invest Detroit · Three Leaf Ventures · Michigan Angel Fund | — | ||
| SEED✓Equity / VC | Aug 2015 | Undisclosed | — | ||
| SPINOUT✓Other financing | Jan 2014 | University of Michigan | — |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 139 |
| 2025 | 141 |
| 2024 | 152 |
| 2023 | 72 |
| 2022 | 68 |
| 2021 | 39 |
| 2020 | 27 |
Growth signals
Genomenon website traffic
Latest recorded traffic for Genomenon is 24K monthly website visits, down 20% over the last three months. Genomenon's team declined 3.5% over the past year.
Hiring
Open positions at Genomenon
Current openings linked to this company in Dealroom.
Comparisons
Genomenon compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Capital deployed
Genomenon investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Talent graph
Genomenon's talent
Source: Dealroom Talent Intelligence.
Investors
21 investors on Genomenon's cap table
Sourced from Dealroom's funding and investor records.
Global footprint
Where Genomenon has talent and traffic
team presence
In the news
Latest news about Genomenon
Recent press, funding announcements, and product moves mentioning Genomenon — open to read from the original sources.
Market sentiment
What the market is saying about Genomenon
An AI-synthesized read of the highest-engagement posts about Genomenon on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Genomenon’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.